Physician

Bradley Cameron Ekstrand, M.D., PH.D.

According to 2025 Medicare claims, Bradley Ekstrand, M.D., PH.D. (NPI: 1528125135) practices medical oncology in the San Francisco-San Mateo-Redwood City, CA market, with the plurality of this provider's patient population coming from San Mateo, CA. This provider's primary affiliated billing organization is UCSF MEDICAL GROUP BUSINESS SERVICES (NPI: 1477624104; TIN: 943281660) and primary practice location at 94010-4145.

Ekstrand's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 454 traditional Medicare patients, billed 158,129 HCPCS/CPT codes, and received $4,042,950 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,366 prescription claims across 202 beneficiaries totaling $4,347,536 in drug costs, led by Erleada (Apalutamide). DME data shows 55 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,338,665 to $4,042,950. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,787,555 to $4,347,536. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $2,887 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	436	53,320	$1,338,665
2016	425	86,968	$1,617,759
2017	422	84,596	$1,953,734
2018	429	88,961	$1,930,711
2019	431	99,767	$1,883,023
2020	362	107,078	$1,835,562
2021	348	95,666	$1,886,525
2022	425	165,665	$3,286,041
2023	447	146,056	$3,280,624
2024	454	158,129	$4,042,950

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	98	614	$1,787,555
2016	94	596	$1,836,763
2017	95	528	$1,554,204
2018	110	585	$2,145,633
2019	127	835	$2,787,516
2020	156	1,052	$3,929,173
2021	159	888	$3,961,767
2022	173	871	$3,000,550
2023	197	1,091	$3,545,451
2024	202	1,366	$4,347,536

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	154	$88,841
2016	12	118	$47,620
2017	N/R	192	$20,314
2018	N/R	216	$17,000
2019	N/R	97	$2,176
2020	N/R	29	$2,903
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	46	$18,125
2024	N/R	55	$1,527

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	69	69	$199
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	136	281	$162
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	269	626	$114
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	296	769	$15
J7030	Infusion, normal saline solution , 1000 cc	83	943	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Erleada	Apalutamide	46	1,380	$656,321
Imbruvica	Ibrutinib	23	644	$497,702
Inlyta	Axitinib	14	660	$363,888
Calquence	Acalabrutinib Maleate	24	720	$332,574
Jakafi	Ruxolitinib Phosphate	19	570	$327,734

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	27	$1,088
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	17	$301
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$138

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Bradley Cameron Ekstrand, M.D., PH.D.?

Tedicare shows public-source Medicare data for Bradley Cameron Ekstrand, M.D., PH.D. (NPI 1528125135), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bradley Cameron Ekstrand, M.D., PH.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Bradley Cameron Ekstrand, M.D., PH.D.?

Bradley Cameron Ekstrand, M.D., PH.D. is linked to UCSF MEDICAL GROUP BUSINESS SERVICES (billing NPI 1477624104) in the available physician profile data.

Does Bradley Cameron Ekstrand, M.D., PH.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.